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Abstract
Objectives—To determine the prevalence
and clinical significance of hepatitis C
virus (HCV) infection in a large cohort of
patients with ‘primary’ Sjögren’s syn-
drome (SS).
Methods—90 consecutive patients (83
female and seven male) were included,
with a mean age of 62 years (range 31-80)
who prospectively visited our unit. All
patients fulfilled the European Commu-
nity criteria for SS and underwent a com-
plete history, physical examination, as
well as biochemical and immunological
evaluation for liver disease. Serum from
all patients was tested for antibodies to
HCV by third generation enzyme linked
immunoassay and positivity was con-
firmed by polymerase chain reaction.
Results—Antibodies to HCV were present
in 13 (14%) patients with ‘primary’ SS.
When compared with patients without
HCV infection, patients with HCV
infection presented a higher prevalence of
hepatic involvement (100% v 8%, p < 0.05).
Transcutaneous liver biopsy was per-
formed in five patients with HCV
infection, and specimens obtained showed
in all cases a chronic active hepatitis with
varying degrees of portal inflammation.
Conclusion—HCV infection is frequent in
patients with ‘primary’ SS and liver
involvement is present in all these
patients. The possible pathogenic role of
HCV infection in these patients is still
unclear.
(Ann Rheum Dis 1997;56:173–175)
Sjögren’s syndrome (SS) is a systemic autoim-
mune disease that mainly aVects exocrine
glands and usually presents as a persistent dry-
ness of the mouth and the eyes caused by func-
tional impairment of the salivary and lacrimal
glands. The histological hallmark is a focal
lymphocytic infiltration of the exocrine glands.
In the absence of an associated systemic
autoimmune disease, patients with this
condition are classified as having ‘primary’ SS.
Viral infection has long been suspected as a
potential cause of SS.1 Specifically, a possible
relation between hepatitis C virus (HCV),
which is a virus that can be excreted in saliva,
and SS has recently been postulated.2
However, information on the prevalence of
HCV infection in ‘primary’ SS is scarce and
reported prevalences show a wide range of
variation depending on the technique to detect
HCV infection.3
The aim of this study was to determine pro-
spectively the prevalence and clinical
significance of HCV infection in a large cohort
of patients with ‘primary’ SS by means of a
third generation enzyme linked immunosorb-
ent assay (ELISA 3) and a polymerase chain
reaction (PCR) assay.
Methods
PATIENTS
We included 90 consecutive patients (83
female and seven male; mean age 62 years;
range 31-80) who attended the Systemic
Autoimmune Diseases Unit from March 1993
until April 1996. All patients were white and
fulfilled four or more of the diagnostic criteria
for SS proposed by the European Community
Study Group in 1993.4 None of these patients
presented clinical or immunological evidence
of other systemic autoimmune disease and no
patient had been previously diagnosed as
having primary biliary cirrhosis or autoim-
mune hepatitis.
All patients underwent a complete history
and physical examination, as well as diagnostic
tests for SS applied according to the
recommendations of the European Commu-
nity Study Group.4 All were systematically
questioned on documented risk factors for
hepatitis virus infection. No patient had previ-
ously received interferon therapy.
LABORATORY STUDIES
Detection of antibodies to HCV
Serum from all patients was tested for HCV
antibodies by a third generation ELISA (Ortho
3.0 Diagnostic Systems, Neckargemund,
Germany). Positivity for HCV infection was
confirmed by second generation recombi-
nant immunoblot assay (RIBA-2;Ortho). In
Annals of the Rheumatic Diseases 1997;56:173–175 173
Systemic Autoimmune
Diseases Unit
M García-Carrasco
M Ramos
R Cervera
J Font
FJ Muñoz
C Miret
G Espinosa
M Ingelmo
and the Department of
Microbiology
J Vidal
Hospital Clínic,
Barcelona, Catalonia,
Spain
Correspondence to:
Dr R Cervera, Unitat de
Malalties Autoimmunes
Sistèmiques, Hospital Clínic,
C/Villarroel, 170, 08036
Barcelona, Catalonia, Spain.
Accepted for publication
2 January 1997
anti-HCV positive serum samples, presence of
HCV-RNA was analysed by PCR (Amplicor
HCV, Roche Diagnostic System). Reverse
transcription and cDNA synthesis were carried
out in a single step reaction using 10 µl of RNA
with specific oligonucleotides NCR1 and
NCR2 5 derived from the well conserved 5’NC
region of HCV.
Other laboratory tests
Hepatitis B surface antigen (HBsAg) was
determined by ELISA. The immunological
tests included antinuclear antibodies (ANA)
(indirect immunofluorescence using mouse
liver as substrate), antimitochondrial antibod-
ies (AMA), antismooth muscle antibodies
(SMA) and antiliver kidney microsome
antibodies type-1 (LKM-1) (indirect immuno-
fluorescence), precipitating antibodies to the
extractable nuclear antigens Ro-SSA and
La-SSB (counterimmunoelectrophoresis), and
rheumatoid factor (latex fixation and
Waaler-Rose tests).
STATISTICAL ANALYSIS
For analysing qualitative diVerences we used a
÷2 test or the Fisher’s exact test when appropri-
ate. For comparison of quantitative param-
eters, Student’s test was used in large samples
of similar variance, and non-parametric Mann-
Whitney U test for small samples. p Values <
0.05 were considered to indicate statistical sig-
nificance. When several independent variables
appeared to have statistical significance in the
univariate analysis, a logistic regression test
was performed for multivariate analysis to rule
out possible confounding variables. In this
case, only those variables showing statistical
significance in the multivariate analysis were
considered as significant in the results of the
study.
Results
Antibodies to HCV (ELISA-3 and RIBA-2)
were present in 13 (14%) of our patients with
‘primary’ SS. They all were positive for
HCV-RNA by PCR. Risk factors for HCV
infection were identified in nine of these
patients (past blood transfusions or surgical
procedures). In four patients no obvious source
of infection was found. When compared with
patients without HCV infection, patients with
this infection presented a higher prevalence of
hepatic involvement (100% v 6%, p<0.05)
(table 1).
Of the 13 patients with ‘primary’ SS and
HCV infection, 12 were female and one male.
Mean age at the onset of clinical manifestations
of the dry syndrome was 55 years (range
40-77) and at the time of protocol was 65 years
(range 53-80). Liver involvement was detected
in all these patients. Nine patients had both
clinical and biochemical features of liver
disease, while the remaining four had raised
liver enzyme activities but were asymptomatic
and without clinical signs of hepatopathy. The
most common clinical manifestation of liver
disease was hepatomegaly, which was present
in eight patients and jaundice, which was seen
in two patients. Biochemical tests showed
increased aminotransferase activities in nine
patients, increased ã-glutamyltransferase in
nine, raised bilirubin in six, and increased alka-
line phosphatase in three patients. Anti-SMA
antibodies were observed in three patients,
AMA were detected in two, and no patient had
positive anti-LKM-1 antibodies. All patients
were negative for HBsAg.
Abdominal ultrasound was performed in all
patients. DiVuse change in liver structure was
detected in seven patients, homogeneous
hepatomegaly in four, and no alteration was
demonstrated in three patients. Transcutane-
ous liver biopsy was performed in five patients
after informed consent. Specimens obtained
showed in all cases a chronic active hepatitis
with varying degrees of portal inflammation.
Other associated histological features were
steatosis in one patient and parenchymal nod-
ules with loss of normal architecture (cirrhosis)
in another patient.
Mean age at detection of liver alteration in
these 13 patients with HCV infection was 61
years (range 46-79) and the follow up of liver
involvement was four years (range 1-18). Only
two patients presented during this follow up
period with clinical manifestations of hepatic
descompensation (ascites, encephalopathy,
peripheral oedema or gastrointestinal bleed-
ing), and diagnosis of hepatocellular carcinoma
was finally diagnosed in both.
Discussion
Our study shows that HCV infection is present
in 14% of the patients with a previously
considered ‘primary’ SS. This prevalence is
significantly high when compared with the
prevalence of HCV infection that has been
found in the general population in Catalonia
(1.2%)6 7 and raises the possibility of a link
between HCV infection and SS. Several
authors8–11 have previously analysed the
prevalence of HCV in SS and this ranges
between 0 and 19% using a RIBA-2 technique.
This wide range of variation may result from a
Table 1 Clinical and immunological manifestations of
patients with ‘primary’ SS and HCV infection compared
with patients without HCV infection
SS with
HCV infection
(n=13)
SS without
HCV infection
(n=77)
Dry mouth 11 (85) 76 (99)
Dry eyes 12 (92) 72 (95)
Parotidomegaly 3 (23) 31 (40)
Splenomegaly 6 (46) 3 (4)
Articular involvement 7 (54) 36 (47)
Raynaud’s phenomenon 4 (31) 10 (13)
Cutaneous vasculitis 3 (23) 8 (10)
Pulmonary involvement 1 (8) 12 (16)
Hepatic involvement 13 (100)* 5 (6)
Peripheral neuropathy 3 (23) 7 (9)
Autoimmune thyroiditis 3 (23) 9 (12)
Thrombocytopenia 6 (46) 7 (9)
Cryoglobulins 6/11 (55) 5/37 (14)
Hypocomplementaemia 4 (31) 9 (12)
ANA (+) 10 (77) 57 (74)
SMA (+) 3 (23) 22 (29)
AMA (+) 2 (15) 0 (0)
RF (+) 8 (62) 29 (38)
Ro-SSA (+) 6 (46) 22 (29)
La-SSB (+) 4 (30) 11 (14)
* p < 0.05. ANA = antinuclear antibodies; SMA = antismooth
muscle antibodies; AMA = antimitochondrial antibodies; RF =
rheumatoid factor. Figures in parentheses are percentages.
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disparity in selection criteria for patient
inclusion or may reflect ethnic or geographical
diVerences.
Dryness of the mouth and the eyes (with
positive ocular and salivary tests),12 lymphoc-
itic infiltration of salivary glands,2 and
positivity of autoantibodies, such as the ANA,
anti-Ro/SS-A, and anti-La/SS-B,13 have
previously been described in patients with
HCV infection. In this study, we describe 13
patients with HCV infection that met at least
four of the six criteria proposed by the
European Community Study Group for the
diagnosis of SS,4 and had no evidence of other
systemic autoimmune disease, thus being con-
sidered as having a ‘primary’ SS. Moreover, in
our group of patients with SS, we have found
an association between HCV infection and
hepatic involvement. Taken these findings
together, it is conceivable that chronic
infection by HCV may originate a ‘secondary’
SS in some patients, although most of these
patients could be in our clinics with a diagnosis
of ‘primary’ SS. It is possible to postulate that
chronic infection by HCV could remain
subclinical during many years, and may be
clinically expressed with features of liver
disease (hepatomegaly or raised aminotrans-
ferase activities) or with the appearance of dry-
ness of the mouth and the eyes.
The relation between HCV infection and SS
might also have therapeutic implications.
Interferon therapy has been used in patients
with HCV infection to treat not only the liver
disease but also extrahepatic manifestations
related to this virus, for example cryoglobuli-
naemia.14 Shiozawa et al15 recently reported a
beneficial eVect of interferon alfa on the xeros-
tomia of SS. However, the possible benefits of
interferon in patients with SS associated to
HCV infection has not been evaluated.
In conclusion, HCV infection is frequently
detected in patients with SS and liver
involvement is present in all these patients. The
possible pathogenetic role of HCV infection in
the extrahepatic manifestations of SS is still
unclear, and potential therapeutic implications
for this combination of diseases remain to be
determined.
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